HomeTagsGilead Sciences

Gilead Sciences

Biotechnology

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

News Desk - February 13, 2024

Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or...

Healthcare

Trodelvy Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer

Business Wire - February 20, 2023

Gilead Sciences, Inc. announced new and updated positive results from three cohorts of the Phase 2 TROPHY-U-01 study of Trodelvy for the treatment of...